Chronic thromboembolic pulmonary hypertension: Medical treatment


Creative Commons License

Ozsu S., Cinarka H.

PULMONARY CIRCULATION, cilt.3, ss.341-344, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 3 Konu: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.4103/2045-8932.114761
  • Dergi Adı: PULMONARY CIRCULATION
  • Sayfa Sayıları: ss.341-344

Özet

Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension ( PAH)-targeted therapy. Advanced medical therapy is considered in patients with inoperable disease, as a bridge to pulmonary endarterectomy or in those with persistent or recurrent pulmonary hypertension. PAH-specific medical therapies include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. The present article will focus on recent developments in the pharmacological treatment of CTEPH.